



Final Appraisal Recommendation

Fentanyl (PecFent[®]▼)

Submission by:
Archimedes Pharma UK Ltd

Advice No: 0911 – July 2011

Recommendation of AWMSG

Fentanyl (PecFent[®]▼) is recommended as an option for use within NHS Wales for the management of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain.

Fentanyl (PecFent[®]▼) should be initiated by, and remain under the supervision of, a specialist physician experienced in the management of opioid therapy in cancer patients.

AWMSG is of the opinion that fentanyl (PecFent[®]▼) may be suitable for shared care within NHS Wales for the above indication.

Additional notes:

Fentanyl (PecFent[®]▼) should only be considered as an option for the management of breakthrough cancer pain when immediate release oral opioids (e.g. morphine, oxycodone) are either inadequate or unsuitable.

Fentanyl (PecFent[®]▼) should be prescribed by brand name to avoid automatic substitution and therefore help with pharmacovigilance.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report, the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion, lay/patient/carer perspective and discussions at AWMSG.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: